Navigation Links
Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma
Date:11/12/2007

WESTMINSTER, Colo., Nov. 12 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced the initiation of patient enrollment in a Phase 1, non-randomized, open-label, multi-center dose escalation study of the Company's targeted chemotherapeutic agent RH1 in patients with advanced solid tumors or non-Hodgkin's lymphoma (NHL).

"We are pleased to advance the development of this agent," said Pablo J. Cagnoni, M.D., Chief Medical Officer of Allos. "RH1 is a small molecule chemotherapeutic agent that is bioactivated by the enzyme DT-diaphorase (DTD), which is over-expressed in many tumors, including lung, colon, breast and liver tumors. We believe that because RH1 is bioactivated in the presence of DTD, it has the potential to preferentially target certain tumors while limiting the amount of toxicity to normal tissue."

In this study, patients with either advanced solid tumors or NHL will receive a 3-hour intravenous (IV) infusion of RH1 administered once every 21 days. Patients will receive starting doses of RH1 at 1.5 mg/m2, with dose escalation in subsequent cohorts based on toxicity. Up to 60 evaluable patients will be enrolled in the study with the objective of determining the maximum tolerated dose (MTD), recommended Phase 2 dose and safety profile of RH1 in this population. Three to six patients will be enrolled per cohort. An expanded cohort of up to 24 evaluable patients who have tumor types with a high likelihood of DTD over-expression will be recruited to explore possible markers of anticancer activity. D. Ross Camidge, M.D., Ph.D., Assistant Professor of Medical Oncology at the University of Colorado Cancer Center, will serve as the study chair.

Information regarding this s
'/>"/>

SOURCE Allos Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015  EP Global Communications, Inc. (Public OTC: EPGL) announced ... the Company about discussing EPGL,s electronic contact lens ... August 3, 2015.  Novartis CEO Joe Jimenez ... coming electronic contact lens market could be worth ... several years.  Novartis partnered with Google in 2014 ...
(Date:7/30/2015)... BOTHELL, Wash. and VANCOUVER ... OGXI ) announced today that it will report ... 13, 2015. Company management will host a conference call ... provide an overview of financial results, clinical development programs ... access the webcast, log on to the Investor Relations ...
(Date:7/30/2015)... THOUSAND OAKS, Calif. , July 30, 2015  Amgen ... Fred Hassan , partner and managing director of Warburg Pincus ... "We are pleased to welcome Fred Hassan and ... to the Amgen Board," said Robert A. Bradway , ... expertise and commitment to innovation will serve Amgen well." ...
Breaking Medicine Technology:Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3
...  With increasing demands for time spreading consumers thin — ... to and from their many appointments — running errands ... simpler for shoppers always on the go, Shopko announces ... to quickly and easily refill and manage their pharmacy ...
... SAN FRANCISCO, Jan. 10, 2012  The University of California, San ... Sanofi (EURONEXT: SAN and NYSE: SNY ) to ... could lead to new therapies for both type 1 and ... will bring together scientists in three UCSF labs with deep ...
Cached Medicine Technology:Shopko Launches Mobile Pharmacy App to Maximize Customer Convenience 2UCSF, Sanofi Collaborate to Find New Diabetes Cures 2UCSF, Sanofi Collaborate to Find New Diabetes Cures 3UCSF, Sanofi Collaborate to Find New Diabetes Cures 4UCSF, Sanofi Collaborate to Find New Diabetes Cures 5
(Date:8/1/2015)... ... August 01, 2015 , ... On Tuesday, July 28th, Symantec released a security ... have been behind the attack on Anthem Inc. which resulted in one of the ... hole attacks and spear phishing campaigns. , For Joe Caruso, founder and ...
(Date:8/1/2015)... ... ... March 19, 2015 Phil Valentine – the Executive Director of Connecticut Community for Addiction Recovery ... off Springer Mountain and heading north. Since that day, Phil has hiked over 1400 miles ... by friends and family. He visited CCAR and left an inspirational message to his ...
(Date:7/31/2015)... Ind. (PRWEB) , ... August 01, 2015 , ... The ... the Global Advisory Panel on the Future of Nursing (GAPFON) 20-21 July 2015 in ... invited to participate in this meeting. , Dr. Silvia Cassiani, Advisor, Nursing and Allied ...
(Date:7/31/2015)... ... July 31, 2015 , ... Recently touted by Becker’s Healthcare ... health analytics , Jvion continues to disrupt the predictive analytic and big data ... patient and population level illness to drive prevention and better health outcomes. Most ...
(Date:7/31/2015)... ... , ... There’s no better way to enjoy the summer weather than by ... next meal, making July the most appropriate to be National Hot Dog Month. King ... Make the next cookout different than the ones in the past. Celebrate National Hot ...
Breaking Medicine News(10 mins):Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3
... ... family’s dreams a reality., , ... (PRWEB) April 1, 2010 -- When Tom Corcoran, owner of Kid Structures in Houston, ... question was not if he would do it but when he could get started. Just days ...
... C are fine for patients with the disease, study ... Every year, hundreds of kidneys are thrown out because ... could help many hepatitis C-infected patients waiting for a ... 1995, more than 3,500 kidneys infected with hepatitis C ...
... Drug Administration (FDA), SNM and the Radiological Society of ... April 13-14, 2010 at the Natcher Conference Center of ... day of the workshop will focus on general issues ... of acquisition, interpretation and analysis of images in clinical ...
... PHOENIX, Ariz. April 1, 2010 Dr. Daniel D. ... has won a top award from the American Society of ... Hoff, M.D., F.A.C.P., will receive the 2010 David A. Karnofsky ... 4-8 at the McCormick Place in Chicago. ASCO will ...
... heart muscle, study found , THURSDAY, April 1 (HealthDay ... factor, or NGF, helped damaged heart muscles function better ... treatments for people who have heart problems, researchers say. ... investigate whether NGF can heal heart cells. Previous research ...
... 5,000 internists (adult medicine specialists), subspecialists, medical students, ... Canada, for Internal Medicine 2010, the annual scientific ... April 22 - 24 (Thursday - Saturday), at ... largest specialty organization devoted to adult medicine and ...
Cached Medicine News:Health News:Kid Structures Prepares Houston's Beach Family for New Adventures 2Health News:Kid Structures Prepares Houston's Beach Family for New Adventures 3Health News:Kid Structures Prepares Houston's Beach Family for New Adventures 4Health News:Hundreds of Donor Kidneys Tossed Away Each Year 2Health News:Hundreds of Donor Kidneys Tossed Away Each Year 3Health News:FDA, SNM and RSNA host April 13-14 two-topic imaging workshop 2Health News:TGen Physician-In-Chief Dr. Daniel D. Von Hoff wins ASCO award 2Health News:All you need to know about adult medicine is at Internal Medicine 2010 2Health News:All you need to know about adult medicine is at Internal Medicine 2010 3Health News:All you need to know about adult medicine is at Internal Medicine 2010 4Health News:All you need to know about adult medicine is at Internal Medicine 2010 5Health News:All you need to know about adult medicine is at Internal Medicine 2010 6
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
PremierEdge™ Clear Cornea Knives - Trapezoid....
The Astigmatome makes precise and accurate cuts for astigmatism correction simply and safely. Depth: 500 to 700....
The Astigmatome makes precise and accurate cuts for astigmatism correction simply and safely....
Medicine Products: